May 20, 2011
Noncommunicable diseases drive lucrative West Africa pharmaceuticals marketBack
Africa|Consulting|Frost|Ghana|Africa|Ghana|Nigeria|USD|Annual Pharmaceuticals Industry Revenues|Pharmaceutical Industry|Pharmaceuticals Industry|Products|Treatment For Diabetes|Chronic Medicines|Communicable And Noncommunicable Diseases|Diabetes|Hypertension|Non-communicable Diseases|Tinotenda Sachikonye|Anti-infectives
© Reuse this
With the adoption of a more western lifestyle, characterised by less healthy diets and more sedentary activities, across West African countries like Nigeria and Ghana, the incidence of non-communicable diseases, particularly hypertension and diabetes, have increased, reports market research and consulting firm Frost & Sullivan.
As the demand for chronic medicines for these conditions surges, lucrative market opportunities, particularly in the generics market, have opened up.
Analysis indicates that the pharmaceutical industry in Ghana and Nigeria earned revenues of $970-million in 2009, and Frost & Sullivan estimates this will reach $2,3-billion in 2016.
“The dual burden of communicable and noncommunicable diseases in Ghana and Nigeria is the main driver for growth of the pharmaceuticals industry in the region,” notes Frost & Sullivan research analyst Tinotenda Sachikonye.
“Second and third, only to anti-infectives, in terms of contribution to the 2009 annual pharmaceuticals industry revenues in Ghana and Nigeria were medicines for cardiovascular conditions and diabetes.”
Treatment for diabetes and cardiovascular conditions, such as hypertension, is typically chronic, thereby creating a continual demand for diabetes and hypertension medicines. Several foreign generics companies have entered the West African market and more local manufacturers are focusing on medicines to treat hypertension and diabetes.
However, as the major proportion of consumers in Ghana and Nigeria are price sensitive, competition with low-cost Asian generics is a challenge for the majority of participants in the market. The cost of conducting business for local manufacturers is particularly high.
“Price is an important purchasing criterion for the Ghana National Health Insurance (NHI), which covers 66,4% of the population in Ghana. The NHI will only pay for generics,” explains Sachikonye. “Further, government tenders in both countries are awarded mainly on the basis of price.”
It is important that companies in this market identify their target customers and differentiate themselves accordingly. Although the majority of consumers in the region are price sensitive, several others are brand loyal and willing to pay the cost for their preferred brands, he says.
“Although pricing is a major determinant of success in Ghana and Nigeria, other factors, such as having good-quality products, having a robust distribution network, good marketing strategies and brand recognition, are equally important. Pharmaceuti-cals companies can leverage these factors to attain a competitive position in the market,” concludes Sachikonye.
Edited by: Chanel de Bruyn© Reuse this Comment Guidelines (150 word limit)
Other Medical and Pharmaceutical Engineering News
Recent Research Reports
Defence 2014: A review of South Africa's defence industry (PDF Report)
Creamer Media’s Defence 2014 report examines South Africa’s defence industry, with particular focus on the key participants in the sector, the innovations that have come out of the sector, local and export demand, South Africa’s controversial multibillion-rand...
Road and Rail 2014: A review of South Africa's road and rail infrastructure (PDF report)
Creamer Media’s Road and Rail 2014 report examines South Africa’s road and rail transport system, with particular focus on the size and state of the country’s road and rail network, the funding and maintenance of these respective networks, and the push to move road...
Real Economy Year Book 2014 (PDF Report)
This edition drills down into the performance and outlook for a variety of sectors, including automotive, construction, electricity, transport, steel, water, coal, gold, iron-ore and platinum.
Real Economy Insight: Automotive 2014 (PDF Report)
This four-page brief covers key developments in the automotive industry over the past 12 months, including an overview of South Africa’s automotive market, trade figures, production and the policies influencing the sector.
Real Economy Insight: Construction 2014 (PDF Report)
This five-page brief covers key developments in the construction industry over the past 12 months. It provides an overview of the sector and includes details of employment in the sector, infrastructure and municipal spending, as well as insight into companies’...
Real Economy Insight: Electricity 2014 (PDF Report)
This five-page brief covers key developments in the electricity industry over the past 12 months, including details of State-owned power utility Eskom’s generation activities, funding and tariffs, independent power producers and prospects for the sector.
This Week's Magazine
JSE-listed real estate investment trust (REIT) Rebosis Property Fund achieved a distribution growth of 8.1% to 99.45c per linked unit in the financial year ended August 31, despite volatile market conditions.
A low-cost, inflatable incubator won this year’s international James Dyson design award, which aims to encourage and inspire the next generation of design engineers.
The World Bank released its ‘Doing Business 2015: Going Beyond Efficiency’ report last month and ranked South Africa 43 out of 189 global economies for its ease of doing business, with Singapore topping the rankings.
Air Products South Africa officially launched its R300-million Eastern Cape air- separation unit (ASU), at its new manufacturing facility in the Coega Industrial Development Zone (IDZ), earlier this month. It is the second facility that Air Products launched in South...
BMW South Africa (SA) has signed a power purchasing agreement with energy company Bio2Watt. The offtake partnership will bring renewable energy to the carmaker’s Rosslyn plant, north of Pretoria.